KR20190102059A - 표적화된 TGF-β 억제를 위한 투약 레지멘 및 투여 형태 - Google Patents

표적화된 TGF-β 억제를 위한 투약 레지멘 및 투여 형태 Download PDF

Info

Publication number
KR20190102059A
KR20190102059A KR1020197022795A KR20197022795A KR20190102059A KR 20190102059 A KR20190102059 A KR 20190102059A KR 1020197022795 A KR1020197022795 A KR 1020197022795A KR 20197022795 A KR20197022795 A KR 20197022795A KR 20190102059 A KR20190102059 A KR 20190102059A
Authority
KR
South Korea
Prior art keywords
cancer
ser
polypeptide
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197022795A
Other languages
English (en)
Korean (ko)
Inventor
이자벨 두솔트
사메르 엘 바와브
율리아 부그메이스터
아카쉬 칸델왈
Original Assignee
메르크 파텐트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메르크 파텐트 게엠베하 filed Critical 메르크 파텐트 게엠베하
Publication of KR20190102059A publication Critical patent/KR20190102059A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Endoscopes (AREA)
KR1020197022795A 2017-01-07 2018-01-05 표적화된 TGF-β 억제를 위한 투약 레지멘 및 투여 형태 Ceased KR20190102059A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762443698P 2017-01-07 2017-01-07
US62/443,698 2017-01-07
US201762581978P 2017-11-06 2017-11-06
US62/581,978 2017-11-06
PCT/US2018/012604 WO2018129331A1 (en) 2017-01-07 2018-01-05 Dosing regimens and dosage forms for targeted tgf-b inhibition

Publications (1)

Publication Number Publication Date
KR20190102059A true KR20190102059A (ko) 2019-09-02

Family

ID=62791283

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197022795A Ceased KR20190102059A (ko) 2017-01-07 2018-01-05 표적화된 TGF-β 억제를 위한 투약 레지멘 및 투여 형태

Country Status (15)

Country Link
US (1) US20190330375A1 (https=)
EP (1) EP3565599A4 (https=)
JP (1) JP2020514290A (https=)
KR (1) KR20190102059A (https=)
CN (1) CN110198738A (https=)
AU (1) AU2018205233A1 (https=)
BR (1) BR112019013924A2 (https=)
CA (1) CA3048646A1 (https=)
CL (1) CL2019001871A1 (https=)
IL (1) IL267856A (https=)
MX (1) MX2019008001A (https=)
PH (1) PH12019501574A1 (https=)
RU (1) RU2019124875A (https=)
SG (1) SG11201906157YA (https=)
WO (1) WO2018129331A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2921805C (en) 2013-08-22 2023-03-07 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
HK1256638A1 (zh) 2015-08-04 2019-09-27 Acceleron Pharma Inc. 用於治疗骨髓增生性病症的方法
LT3628049T (lt) 2017-05-04 2023-08-25 Acceleron Pharma Inc. Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
JP2021528399A (ja) * 2018-06-22 2021-10-21 メルク パテント ゲーエムベーハー 胆道癌を治療する際に使用するための標的ＴＧＦ−β阻害のための投薬計画
SG11202013190YA (en) * 2018-07-02 2021-01-28 Merck Patent Gmbh Combination therapy with targeted tgf-b inhibition for treatment of advanced non-small cell lung cancer
WO2020014285A2 (en) 2018-07-09 2020-01-16 Intrexon Corporation Fusion constructs and methods of using thereof
US12559539B2 (en) * 2018-11-09 2026-02-24 Jiangsu Hengrui Medicine Co., Ltd. TGF-beta receptor fusion protein pharmaceutical composition and use thereof
AR117918A1 (es) 2019-01-30 2021-09-01 Scholar Rock Inc COMPLEJOS-ESPECÍFICOS LTBP INHIBIDORES DE TGFb Y SUS USOS
CA3135988C (en) 2019-06-10 2024-11-19 Shandong Boan Biotechnology Co., Ltd. Bifunctional fusion protein against PD-L1 and TGFS and its use
CN112574314A (zh) * 2019-09-30 2021-03-30 和铂医药(苏州)有限公司 一种融合蛋白及其应用
EP4049012A1 (en) * 2019-10-24 2022-08-31 Amgen Inc. Systems and approaches for drug delivery
EP4051279A1 (en) * 2019-11-01 2022-09-07 Ares Trading S.A. COMBINED INHIBITION OF PD-1, TGFß AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER
WO2021092079A1 (en) 2019-11-05 2021-05-14 Acceleron Pharma Inc. Treatments for systemic sclerosis
AU2020402496A1 (en) * 2019-12-11 2022-06-16 WuXi Biologics Ireland Limited Bi-functional antibody against PD-L1 and TGFβ
JP7730817B6 (ja) * 2019-12-20 2025-09-26 アレス トレーディング ソシエテ アノニム ＩｇＧ：ＴＧＦβＲＩＩ融合タンパク質組成物
CN111118064B (zh) * 2019-12-24 2022-10-25 华南理工大学 一种精子生成障碍动物模型及其制备方法与应用
AU2021205440A1 (en) 2020-01-11 2022-09-01 Scholar Rock,Inc. TGF-beta inhibitors and use thereof
US20230057012A1 (en) 2020-01-11 2023-02-23 Scholar Rock, Inc. Tgfb inhibitors and use thereof
WO2021164701A1 (en) * 2020-02-18 2021-08-26 Nanjing GenScript Biotech Co., Ltd. Fusion proteins and uses thereof
US20230072133A1 (en) * 2020-02-25 2023-03-09 WuXi Biologics Ireland Limited A bifunctional fusion protein and uses thereof
EP4178680A4 (en) 2020-07-10 2024-07-31 Precigen, Inc. FUSION CONSTRUCTS AND THEIR METHODS OF USE
WO2022063193A1 (zh) * 2020-09-24 2022-03-31 上海齐鲁制药研究中心有限公司 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
US20240148903A1 (en) 2021-03-08 2024-05-09 Nanjing GenScript Biotech Co., Ltd. Delivery of antibody by using dual viral vector system
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
CA3231649A1 (en) * 2021-11-19 2023-05-25 Cecilia Anna Wilhelmina Geuijen Multispecific binding moieties comprising pd-1 and tgf-brii binding domains
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785682A (en) * 1995-03-22 1998-07-28 Abbott Laboratories Pre-filled syringe drug delivery system
CA3083324A1 (en) * 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
US20130110045A1 (en) * 2011-10-31 2013-05-02 Ming-Yuan Wu Single use intravenous therapy administering device with needle safety covers
CN110563850A (zh) * 2012-04-30 2019-12-13 比奥孔有限公司 靶向/免疫调节性融合蛋白及其制造方法
JP6720075B2 (ja) * 2013-05-31 2020-07-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌のための併用療法
US9676863B2 (en) * 2014-02-10 2017-06-13 Merck Patent Gmbh Targeted TGFβ inhibitors
TWI716362B (zh) * 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
US10828353B2 (en) * 2015-01-31 2020-11-10 The Trustees Of The University Of Pennsylvania Compositions and methods for T cell delivery of therapeutic molecules
EP3770171A1 (en) * 2015-04-03 2021-01-27 XOMA Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
RS61152B2 (sr) * 2015-05-12 2024-06-28 Hoffmann La Roche Terapeutski i dijagnostički postupci za lečenje raka

Also Published As

Publication number Publication date
JP2020514290A (ja) 2020-05-21
CA3048646A1 (en) 2018-07-12
SG11201906157YA (en) 2019-08-27
CN110198738A (zh) 2019-09-03
MX2019008001A (es) 2019-09-09
EP3565599A1 (en) 2019-11-13
PH12019501574A1 (en) 2019-11-04
AU2018205233A1 (en) 2019-07-11
RU2019124875A (ru) 2021-02-08
US20190330375A1 (en) 2019-10-31
EP3565599A4 (en) 2020-07-01
CL2019001871A1 (es) 2019-12-13
BR112019013924A2 (pt) 2020-02-11
RU2019124875A3 (https=) 2021-07-08
WO2018129331A1 (en) 2018-07-12
IL267856A (en) 2019-09-26

Similar Documents

Publication Publication Date Title
KR20190102059A (ko) 표적화된 TGF-β 억제를 위한 투약 레지멘 및 투여 형태
AU2019246876B2 (en) Targeted TGFß Inhibition
KR20230125859A (ko) 암에 대한 조합 요법
KR20210020098A (ko) Iii기 nsclc의 치료 및 치료와 연관된 병리학적 상태의 완화
US20210061899A1 (en) Dosing regimens for targeted tgf-b inhibition for use in treating cancer in treatment naïve subjects
US20210115145A1 (en) Combination therapy with targeted tgf-b inhibition for treatment of advanced non-small cell lung cancer
US20210214446A1 (en) Dosing regimens for targeted tgf-b inhibition for use in treating biliary tract cancer
HK40050217A (en) Combination therapy with targeted tgf-b inhibition for treatment of advanced non-small cell lung cancer
HK40042110A (en) Dosing regimens for targeted tgf-b inhibition for use in treating cancer in treatment naive subjects
HK40012523A (en) DOSING REGIMENS AND DOSAGE FORMS FOR TARGETED TGF-β INHIBITION
HK40050239A (en) Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment
HK40049078A (en) Dosing regimens for targeted tgf-β inhibition for use in treating biliary tract cancer
HK40064486A (en) TARGETED TGFβ INHIBITION

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190802

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210105

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230424

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231108

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230424

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I